Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

NCT03988452 - Darunavir + Lamivudine + Ritonavir + Zidovudine vs Darunavir + Lamivudine + Ritonavir + Tenofovir disoproxil vs Dolutegravir + Lamivudine + Zidovudine vs Dolutegravir + Lamivudine + Tenofovir disoproxil & Acquired Immune Deficiency Syndrome (AIDS) / HIV

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Dolutegravir, in combination with NRTIs, was effective in the treatment of patients with HIV-1 infection, including those with marked NRTI resistance who were not predicted to be active by NRTIs. Tenofovir was not inferior to zidovudine as second-line therapy.
Paton et al. 2021 N Engl J Med 385: 330-341…

References (Sources)

Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV
Paton et al. 2021 N Engl J Med 385: 330-341

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

NCT03988452 - Darunavir + Lamivudine + Ritonavir + Zidovudine vs Darunavir + Lamivudine + Ritonavir + Tenofovir disoproxil vs Dolutegravir + Lamivudine + Zidovudine vs Dolutegravir + Lamivudine + Tenofovir disoproxil & Acquired Immune Deficiency Syndrome (AIDS) / HIV

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat

Links